8-K: VYNE Therapeutics' Vitiligo Drug Fails Primary Endpoint in Phase 2b Trial, Company Seeks Partner

VYNE Therapeutics announced disappointing topline results from its Phase 2b trial of Repibresib gel for nonsegmental vitiligo, missing primary and key secondary endpoints, leading to trial termination and a search for an external partner.

Summary

• VYNE Therapeutics' Phase 2b trial for Repibresib gel in nonsegmental vitiligo, involving 177 subjects, did not meet its primary endpoint of F-VASI50 at week 24 compared to vehicle.
• The trial also missed a key secondary endpoint of F-VASI75.
• The highest dose (Repibresib 3%) showed a nominally statistically significant treatment effect in percent change-from-baseline (CFB) in F-VASI score (-43.6% vs. vehicle -25.6%, p=0.0020) and T-VASI score (-28.3% vs. vehicle -16.2%, p=0.0436) at week 24.
• Results were impacted by an unusually high vehicle effect and higher-than-expected dropout rates in active arms (Repibresib 3%: 36.6%; Repibresib 2%: 30.2%; Repibresib 1%: 26.1%) compared to vehicle (10.6%).
• The company will discontinue treatment in the ongoing extension phase and terminate the trial for Repibresib.
• VYNE Therapeutics plans to seek an external development and commercialization partner for Repibresib.
• Unaudited cash, cash equivalents, and investments were approximately $39.6 million as of June 30, 2025.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to the failure of the primary and key secondary endpoints of the Phase 2b trial, leading to the termination of the program and the need to seek a partner. While some positive signals were seen in secondary endpoints and the company maintains confidence in its platform, the immediate outcome for Repibresib is a significant setback.

Positives

• The highest dose (Repibresib 3%) demonstrated nominally statistically significant improvements in percent change-from-baseline in F-VASI score (-43.6% vs. vehicle -25.6%, p=0.0020) and T-VASI score (-28.3% vs. vehicle -16.2%, p=0.0436) at week 24.
• The majority of skin-related treatment emergent adverse events (TEAEs) were mild in severity (76.0%) and resolved during the study.
• There was no clear dose-dependent increase in the frequency of skin-related TEAEs.
• No increased risk of thrombocytopenia or GI-related serious adverse events was observed.
• The company maintains confidence in its InhiBET™ BET inhibitor platform for other immune-mediated diseases.

Negatives

• The Phase 2b trial for Repibresib gel in nonsegmental vitiligo did not meet its primary endpoint (F-VASI50) or a key secondary endpoint (F-VASI75) compared to vehicle.
• The trial results were negatively impacted by an unexpectedly high treatment effect observed in the vehicle arm.
• Higher-than-expected dropout rates were observed in the active treatment arms (Repibresib 3%: 36.6%; Repibresib 2%: 30.2%; Repibresib 1%: 26.1%) compared to the vehicle arm (10.6%).
• The company will discontinue the ongoing extension phase of the trial and terminate the Repibresib program.
• A higher rate of overall treatment emergent adverse events (TEAEs) was observed for subjects receiving Repibresib gel compared to vehicle.
• Eight subjects receiving Repibresib gel discontinued due to an adverse event, compared to none in the vehicle arm.

Risks

• Inability to successfully develop product candidates.
• Uncertainty regarding the timing of commencement of future preclinical studies and clinical trials.
• Inability to complete and receive favorable results from clinical trials of product candidates.
• Challenges in finding a suitable development and commercialization partner for Repibresib.
• Difficulty in obtaining additional funding through equity or debt financing transactions or collaboration arrangements.
• Potential inability to comply with various regulations applicable to the business.
• Preliminary financial estimates are subject to change pending completion of full financial statements.

Future Outlook

The company intends to seek a development and commercialization partner for Repibresib following the trial results. An update on plans, including those for the oral BET inhibitor VYN202, is expected in the coming weeks.

Management Comments

• "We are disappointed with the results of our Phase 2b trial, which were impacted by an unexpectedly high treatment effect in the vehicle arm and a high discontinuation rate in the active arms."
• "Although we missed our F-VASI50 and F-VASI75 endpoints, we did see a meaningful reduction in the percent change from baseline in both F-VASI and T-VASI for our highest dose and are conducting a thorough evaluation of the full dataset to analyze any other data that may inform the results and our strategic next steps."
• "Vitiligo remains an area of significant unmet need and we are grateful to the patients, investigators, and clinical staff who participated in the trial."
• "Despite this outcome, we remain confident in the potential of our InhiBET™ BET inhibitor platform as a promising and innovative mechanistic approach for the treatment of a broad range of serious immune-mediated diseases."
• "We intend to seek a development and commercialization partner for Repibresib and we will provide an update on our plans, including those for our oral BET inhibitor VYN202, in the coming weeks."

Industry Context

Vitiligo remains an area of significant unmet medical need. VYNE Therapeutics' InhiBET™ BET inhibitor platform represents an innovative mechanistic approach for treating a broad range of immune-mediated diseases, positioning the company within the competitive landscape of biopharmaceutical firms developing therapies for chronic inflammatory and autoimmune conditions.

Comparison to Industry Standards

• Overall discontinuation rates for all Repibresib arms were higher than treatment arms in Phase 2b and Phase 3 studies for approved and late-stage vitiligo therapies, as referenced by the company.
• Discontinuation rates due to adverse events for all Repibresib arms were comparable to treatment arms in Phase 2b and Phase 3 studies for approved and late-stage vitiligo therapies, as referenced by the company.
• The filing does not name specific comparable companies, projects, or their detailed results.

Stakeholder Impact

• Shareholders: Likely negative impact due to the failure of a key clinical trial, leading to program termination and potential dilution if future capital raises are equity-based.
• Patients: Disappointment for patients with nonsegmental vitiligo who were hoping for a new treatment option from Repibresib.
• Employees: Potential impact on employees involved in the Repibresib program, though the company's broader platform (VYN202) continues.
• Partners: The company is seeking a new partner for Repibresib, indicating a shift in its development strategy for this asset.

Next Steps

• Conduct a thorough evaluation of the full dataset to analyze other data that may inform results and strategic next steps.
• Seek a development and commercialization partner for Repibresib.
• Provide an update on plans, including those for the oral BET inhibitor VYN202, in the coming weeks.

Key Dates

Recommendation

The failure of the primary and key secondary endpoints in a Phase 2b trial for a lead asset (Repibresib) is a significant negative catalyst. The decision to terminate the trial and seek an external partner indicates a lack of confidence in continuing internal development, which will likely lead to a substantial decline in share price. While the company has other assets and cash, the immediate outlook for this program is poor, warranting a sell recommendation for investors.

Keywords

VYNE Therapeutics, Repibresib, Vitiligo, Phase 2b Trial, Clinical Trial Results, Biopharmaceutical, Dermatology, Autoimmune Disease, BET Inhibitor, Drug Development, Nonsegmental Vitiligo, F-VASI, T-VASI, Clinical Stage, Nasdaq: VYNE